Radioligand therapies (RLT) addressing the prostate-specific membrane antigen (PSMA), have shown most promising results regarding clinical safety and efficacy in patients with progressive metastasized castration-resistance prostate cancer (mCRPC) that are no longer responsive to treatments based on current guidelines [1,2,3,4,5]. The gene discussed is FOLH1; the disease is prostate cancer.